新型生物标志物预测乙肝感染自然病程的临床意义

StephenW

新型生物标志物预测乙肝感染自然病程的临床意义
吴伟康 1 2、袁小杰 1 、张伟禄 1 、周浩伟 1 、孔翔宇 1 、振赫 1 、傅婷 1 、张文华 3 、贾文玲 3 、梁春晖 3 、唐海涛 3 、王凤梅 3 、盐城叶 4 , 邵中军 1 , 季兆华 1
隶属关系
隶属关系

    1个
    空军军医大学公共卫生学院流行病学系特种作战环境危害评价与控制教育部重点实验室，中国西安。
    2个
    甘肃中医药大学，兰州，中国。
    3个
    【作者单位】： 甘肃省武威市肿瘤医院肝胆中心;
    4个
    【作者单位】： 甘肃省武威市肿瘤医院临床药物实验所

    PMID：36388269 PMCID：PMC9650535 DOI：10.3389/fpubh.2022.1037508

抽象的

背景与目的：慢性乙型肝炎（CHB）可分为免疫耐受（IT）、免疫清除（IC）、乙型肝炎e抗原（HBeAg）阴性非活动/静止携带者（ENQ）和HBeAg阴性肝炎（ENH）。 ）阶段。用于区分这些阶段的常规生物标志物具有局限性。我们检查了乙型肝炎病毒 (HBV) RNA 和乙型肝炎核心相关抗原 (HBcrAg) 作为新型生物标志物的临床意义。

方法：189 名目前未接受治疗的患者按 CHB 阶段进行分类（IT = 46，IC = 45，ENQ = 49，ENH = 49）。分析了 HBV RNA 和 HBcrAg 与 HBV DNA 和丙氨酸转氨酶 (ALT) 的关联。决策树模型用于区分 CHB 自然过程中的四个阶段。

结果：HBV RNA 和 HBcrAg 浓度在 IT 和 IC 期最高（P < 0.01）。初治患者的血清 HBV RNA 与 HBcrAg 相似。 HBV RNA 和 HBcrAg 在 HBeAg+ 和 HBeAg- 状态下与 HBV DNA 相关（HBV RNA：e+ r = 0.51，e- r = 0.62；HBcrAg：e+ r = 0.51，e- r = 0.71），但它们与 HBV DNA 相关各阶段不同。 HBcrAg 与 ALT 在区分 CHB 阶段的准确性、敏感性和特异性分别为 95.65%、95.83% 和 95.55%。

结论：血清 HBV RNA 和 HBcrAg 可能有助于监测 CHB 进展。

关键词：乙肝病毒DNA；乙肝病毒核糖核酸；乙肝抗原；乙型肝炎；新型生物标志物；阶段。

版权所有 © 2022 Wu、Yuan、Zhang、Zhou、Kong、He、Fu、Zhang、Jia、Liang、Tang、Wang、Ye、Shao 和 Ji。
利益冲突声明

作者声明该研究是在没有任何可能被解释为潜在利益冲突的商业或财务关系的情况下进行的

StephenW

Clinical significance of novel biomarkers to predict the natural course of hepatitis B infection
Weikang Wu  1   2 , Xiaojie Yuan  1 , Weilu Zhang  1 , Haowei Zhou  1 , Xiangyu Kong  1 , Zhen He  1 , Ting Fu  1 , Wenhua Zhang  3 , Wenling Jia  3 , Chunhui Liang  3 , Haitao Tang  3 , Fengmei Wang  3 , Yancheng Ye  4 , Zhongjun Shao  1 , Zhaohua Ji  1
Affiliations
Affiliations

    1
    Ministry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, Department of Epidemiology, School of Public Health, Air Force Medical University, Xi'an, China.
    2
    Gansu University of Chinese Medicine, Lanzhou, China.
    3
    Hepatobiliary Center, Wuwei Cancer Hospital of Gansu Province, Wuwei, China.
    4
    Clinical Drug Experiment Institution, Wuwei Cancer Hospital of Gansu Province, Wuwei, China.

    PMID: 36388269 PMCID: PMC9650535 DOI: 10.3389/fpubh.2022.1037508

Abstract

Background and aim: Chronic hepatitis B (CHB) can be divided into immune tolerance (IT), immune clearance (IC), hepatitis B e antigen (HBeAg)-negative inactive/quiescent carrier (ENQ), and HBeAg-negative hepatitis (ENH) phases. The conventional biomarkers used to distinguish these phases have limitations. We examined the clinical significance of hepatitis B virus (HBV) RNA and hepatitis B core-related antigen (HBcrAg) as novel biomarkers.

Methods: One hundred eighty-nine patients without treatment currently were categorized by CHB phase (IT = 46, IC = 45, ENQ = 49, ENH = 49). The associations of HBV RNA and HBcrAg with HBV DNA and alanine transaminase (ALT) were analyzed. The decision tree model was used to distinguish the four phases in the natural course of CHB.

Results: The concentrations of HBV RNA and HBcrAg were highest in the IT and IC phases (P < 0.01). Serum HBV RNA was similar to HBcrAg in treatment-naïve patients. HBV RNA and HBcrAg correlated with HBV DNA in the HBeAg+ and HBeAg- status (HBV RNA: e+ r = 0.51, e- r = 0.62; HBcrAg: e+ r = 0.51, e- r = 0.71), but their association with HBV DNA differed among phases. The accuracy, sensitivity, and specificity of HBcrAg with ALT in distinguishing the CHB phases were 95.65%, 95.83%, and 95.55%, respectively.

Conclusion: Serum HBV RNA and HBcrAg may be useful to monitor CHB progression.

Keywords: HBV DNA; HBV RNA; HBcrAg; hepatitis B; novel biomarkers; phase.

Copyright © 2022 Wu, Yuan, Zhang, Zhou, Kong, He, Fu, Zhang, Jia, Liang, Tang, Wang, Ye, Shao and Ji.
Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest